A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Study for Patients with Anaplastic Astrocytoma That Progress/Recur After Radiation and Chemotherapy (Brain Tumors)
Sponsor: Orbus Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ9886
U.S. Govt. ID: NCT02796261
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Anaplastic astrocytoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator